NEW YORK, NY--(Marketwired - March 27, 2014) -
IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC
), a regenerative medicine company utilizing adult autologous vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that at the Stand For The Troops event in Washington, D.C. last Saturday, March 23, Major General John Batiste, US Army (Ret.) and Major Ben Richards, US Army (Ret.) the brain trauma veteran who received his purple heart, thanked our CEO, Steven Victor, MD for his help with brain trauma veterans.
IntelliCell BioSciences in collaboration with Dr. Sandlin Lowe will be conducting investigational clinical protocol trials for brain trauma in the near future. Veterans experiencing symptoms of brain trauma are prime candidates for the study.
IntelliCell's Chief Executive Officer, Dr. Victor, remarked, "This is a tremendous honor and it's a great feeling to know that there is hope for a significant improvement in the quality of life for these dedicated soldiers who suffer from brain trauma. We, at IntelliCell, are excited to have this opportunity to work with the distinguished neuropsychiatric, Dr. Lowe, and start investigational clinical studies.
According to Eilhys England Hackworth, Co-Founder and Chair of Stand For The Troops, "It was especially appropriate to open our event, the first annual Bacon Brothers Concert with Major Ben Richards, US Army (Ret.) receiving the Purple Heart from former U.S. Army Vice Chief of Staff, General Peter Chiarelli. It was equally appropriate to acknowledge and have present the two doctors who treated Ben for his traumatic brain injury: Dr. Paul Harch, who used hyperbaric oxygen and Dr. Steven Victor, who used autologous stem cell therapy. Ben probably would not be able to comfortably stand on stage to accept his purple heart without these pro bono treatments from both of these doctors."
About IntelliCell Biosciences
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology-licensing agreements with technology developers, universities, and international business entities.
About Stand For The Troops
Soldiers For The Truth has become Stand For The Troops. Our new name reflects exactly what we do on behalf of all concerned Americans -- stand for the troops -- and more specifically, stand for our frontline troops, our young heroes who stand tall for us and our country out at the tip of the spear. For more information go to: http://sftt.org/
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.